RESPIRE
Financiado
Development of the first oral disease-modifying treatment for chronic obstructiv...
Development of the first oral disease-modifying treatment for chronic obstructive pulmonary disease (COPD)
Palobiofarma is a Spanish biotech company with the ambition to develop new treatments for cancer and autoimmune diseases based on adenosine receptor modulation. Our compound PBF-680 is a first-in-class therapy with disease modifyi...
Palobiofarma is a Spanish biotech company with the ambition to develop new treatments for cancer and autoimmune diseases based on adenosine receptor modulation. Our compound PBF-680 is a first-in-class therapy with disease modifying effects in respiratory diseases like COPD. Over 65M
patients suffer from COPD, yet there are no approved therapies that target disease progression. PBF-680 is a unique molecule designed to specifically antagonise the Adenosine 1 Receptor (A1R). it has shown to be safe and well-tolerated in phase 1 trials and demonstrated to reduce pulmonary
symptoms and inflammation in mild-to-moderate asthmatics in phase 2 trials. With funding from the EIC Accelerator, we will demonstrate efficacy in a phase 2 trial in COPD, a market with high unmet medical need. Proven clinical efficacy will be the major milestone to raise €30M (incl €15M EIC
Equity) for a phase 3 trial, followed by an additional fund raising or IPO to independently reach market launch with PBF-680.
ver más
Duración del proyecto: 20 meses
Fecha Inicio: 2022-10-06
Fecha Fin: 2024-06-30
Fecha Fin: 2024-06-30
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-06-30
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
HORIZON-EIC-2021-ACCELERATOROPEN-01:
EIC Accelerator Open 2021
Cerrada
hace 2 años
Presupuesto
El presupuesto total del proyecto asciende a
4M€
Líder del proyecto
PALO BIOFARMA
La investigacion, fabricacion, comercializacion, distribucion y venta de productos farmaceuticos
Perfil tecnológico
TRL
3-4
2M
Perfil tecnológico
TRL
3-4
2M